WAIT: Do not buy into breakdown at $340. Wait for confirmed daily close above 10 EMA at $351 (ideally also above Bollinger middle at $353). If forced to enter now, cap at 25% of planned position (not 50%), set stop at $310 (not 290), add 15-trading-day time stop. Target re-entry zone of $300-320 on retest.

• Q3 FY26 85.5% YoY revenue growth is deal-driven (VMware consolidation), not organic silicon acceleration
• Forward P/E of 17.7x is consensus estimate ($19.38 EPS), not a fact—if earnings miss by 15%, P/E rises to ~20x with decelerating momentum
• Bear case expected value of +$13/share = less than 4% return on $340 stock with 1.46 beta—this is not a margin of safety
• Technical: Price below 10 EMA ($351), 50 SMA ($373), 200 SMA ($366), VWMA ($351); MACD negative, RSI 39.8 is neutral not oversold
• No oversold reading on this decline suggests selling has not been exhausted—more downside likely
• 10Y yields at 2002 highs, Polymarket pricing 26% probability of October rate hike—zero probability of Fed cut
• Easy money tailwind that powered semis in 2024/early 2025 is gone; long-duration growth stocks vulnerable
• Zero AVGO headlines over 7 days is an information vacuum, not a quiet accumulation zone
• Receivables nearly doubled YoY to $20.9B—warrants monitoring DSO; AR growing faster than revenue raises quality concerns
• Customer concentration risk is structural, not neutralized by large TAM; single hyperscaler slowdown would materially impact revenue
• If September low at $344 breaks, next support at $336 (lower Bollinger), then February low at $320, then $290 (16% below current)
• Lower stop to $310 to reflect realistic probability of February low test, not $290 (52-week low)
• 15-day time stop forces discipline rather than hoping falling knife eventually turns
• If position must be taken now, cap at 25% of planned total, not 50%—at 25% with 1.46 beta, position is concentrated bet, not diversified

→ vs aggressive: VMware acquisition consolidated software revenue onto top line—this is not organic acceleration in the silicon franchise; stripping out VMware reveals far less dramatic growth

→ vs aggressive: 17.7x forward P/E is a consensus estimate with history of being too optimistic on AI-exposed names during revenue mix shifts; if forward EPS comes in 15% below consensus, P/E rises to ~20x with decelerating momentum

→ vs aggressive: Bear case EV of +$13/share = less than 4% expected return on $340 stock with 1.46 beta—actual floor could be $15-20 below that given input uncertainty; this is not asymmetry, it's a rounding error

→ vs aggressive: MACD histogram flipping positive is a one-bar data point on single indicator described as 'early stage and unconfirmed'—catching a falling knife because one momentum oscillator printed green is not risk management

→ vs aggressive: Saying 10Y at 2002 highs is 'already priced in' cannot be known with certainty; Polymarket pricing 26% probability of October rate hike is not a tail event

→ vs aggressive: Zero news over 7 days is an information vacuum, not quiet accumulation—absence of evidence is not evidence of opportunity; default should be to reduce exposure, not increase it

→ vs aggressive: Receivables up ~85% YoY to $20.9B warrants scrutiny of DSO trends; strong OCF ($14.2B) does not fully address whether extended terms or supply-chain pull-forward are distorting the picture

→ vs aggressive: Customer concentration is a structural feature, not neutralized by TAM size—large TAM means more revenue at stake if a hyperscaler delays custom silicon roadmap or brings work in-house

→ vs neutral: Phased entry framework is reasonable but stop at $290 is too wide; 52-week low stop without oversold signal means February low at $320 and lower Bollinger at $336 are realistic intermediate stops en route to $290

Phased entry: 30-35% first tranche at 330-345, stop at 315; reserve second tranche for 300-320 zone; 25-day reassessment trigger; defined exit ahead of FOMC meeting; do not chase relief rallies

• Bear case expected value of $13 on a 340 stock (3.8% return) is not margin of safety given 1.46 beta and confirmed breakdown below all major moving averages
• RSI at 39.8 has not hit oversold—selling hasn't been exhausted; MACD histogram flipping green for one bar is noise, not confirmation of a bottom
• Information vacuum (no analyst notes, no retail sentiment data, no company news) means conviction is lower and should translate to smaller positions, not larger ones
• 17.7x forward earnings skepticism is fair but the 15% downside miss scenario is a tail risk, not the base case; AI capex cycle is supported by Accenture bookings, IBM 2027 outlook, and Anthropic compute spend
• Waiting for daily close above 351 plus Bollinger middle at 353 means buying 2.3-2.7% higher when earnings come roughly every 13 weeks; time decay on forward P/E is real cost
• 15-day time stop is too tight; high-beta basing structure in hawkish macro does not form in 15 trading days; push to 25 days as reassessment trigger, not automatic exit
• First tranche of 30-35% balances participation if re-rating starts now while keeping drawdown manageable if chart breaks toward 320 or 290
• Aggressive analyst over-exposed to first move; conservative analyst under-exposed to second move from depressed levels where re-rating can be fast and violent
• Macro headwind partially discounted but Polymarket shows 26% hike probability resolving in 28 trading days; argues for defined timeline on trade rather than holding through FOMC meeting
• 10Y at 2002 highs is partially discounted but intensifying would be live risk; polymorphic probability is real, not tail

→ vs aggressive: Bear case expected value of $13 is being misused—bounded downside is not the same as small downside, especially with 1.46 beta and confirmed breakdown below all major moving averages

→ vs aggressive: MACD histogram flipping green for one bar on a stock making new closing lows in a downtrend is noise, not confirmation; RSI at 39.8 not oversold means more selling ahead

→ vs aggressive: 50% first tranche at 330-345 is too large given information vacuum and visibility constraints; should be 30-35%, not 50%

→ vs conservative: Treating 15% downside miss as base case when AI capex cycle has real support from Accenture, IBM, and Anthropic; tail risk should be sized for, not assumed as base

→ vs conservative: Waiting for 351 entry costs 2.3-2.7% in a name with ~13 week earnings cycle; time decay on forward P/E is real and forward estimates roll forward while waiting

→ vs conservative: 15-day time stop is too tight for a basing structure in high-beta name with hawkish macro overlay; 25 days as reassessment trigger is more appropriate than automatic exit

→ vs conservative: Catching most of the move is incorrect—in a name with 0.35 PEG and forward earnings growth, re-rating from depressed levels is fast and violent; you catch the second or third leg, missing 15-20% of the first leg